Evidence map›Paper›PMID 38458657›Full record

GuidelineESMO open2024

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.

J Herrstedt, R Clark-Snow, C H Ruhlmann, A Molassiotis, I Olver, B L Rapoport, M Aapro, K Dennis, P J Hesketh, R M Navari and 24 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in ESMO open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Olanzapine (10 mg vs 5 mg vs 2.5 mg) for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) - a systematic review and network meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Multi-day vs single-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Pooled it
  12. Guideline
  13. Pooled it
  14. A phase 2 pharmacokinetic and pharmacodynamic dose-finding study of oral NEPA for chemotherapy-induced nausea and vomiting in pediatric patients with cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

J HerrstedtDepartment of Clinical Oncology, Zealand University Hospital Roskilde and Naestved, Roskilde; Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
R Clark-SnowOncology Supportive Care Consultant, Overland Park, USA.
C H RuhlmannDepartment of Oncology, Odense University Hospital, Odense; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
A MolassiotisCollege of Arts, Humanities and Education, University of Derby, Derby, UK.
I OlverFaculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.
B L RapoportThe Medical Oncology Centre of Rosebank, Johannesburg; Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
M AaproGenolier Cancer Center, Genolier, Switzerland.
K DennisDivision of Radiation Oncology, The Ottawa Hospital and the University of Ottawa, Ottawa, Canada.
P J HeskethDivision of Hematology Oncology, Lahey Hospital and Medical Center, Burlington.
R M NavariWorld Health Organization, Birmingham.
L SchwartzbergWilliam N. Pennington Cancer Institute, University of Nevada, Reno School of Medicine, Reno.
M L AffrontiDepartment of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham; Duke University School of Nursing, Duke University, Durham, USA.
M A Garcia-Del-BarrioPharmacy Department, Clínica Universidad de Navarra, Madrid; School of Pharmacy and Nutrition, Universidad de Navarra, Pamplona, Spain.
A ChanDepartment of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, USA.
L CelioIndependent Medical Oncologist, Milan, Italy.
R ChowTemerty Faculty of Medicine, University of Toronto, Toronto, Canada.
M FleuryDepartment of Oncology, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
R J GrallaAlbert Einstein College of Medicine, Jacobi Medical Center, Bronx, USA.
R GiustiMedical Oncology Unit, Sant' Andrea Hospital of Rome, Rome, Italy.
F JahnClinic for Internal Medicine IV, Oncology - Hematology - Hemostaseology, University Hospital Halle (Saale), Halle, Germany.
H IiharaDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.
E MaranzanoUniversity of Perugia, Perugia, Italy.
V RadhakrishnanDepartment of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, India.
M SaitoDepartment of Breast Oncology, Juntendo University School of Medicine, Tokyo, Japan.
P SayeghDepartment of Pharmacy, OU Health Stephenson Cancer Center, Oklahoma City, USA.
S BosnjakDepartment of Supportive Oncology and Palliative Care, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
L ZhangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
J LeeCollege of Nursing and Mo-Im Kim Nursing Research Institute, Yonsei University, Seoul, Korea.
V OstwalDepartment of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
T SmitThe Medical Oncology Centre of Rosebank, Johannesburg.
A ZilicDepartment of Supportive Oncology and Palliative Care, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
K JordanDepartment of Hematology, Oncology and Palliative Medicine, Ernst von Bergmann Hospital, Potsdam; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany.
F Scotté∗Interdisciplinary Patient Pathway Division, Gustave Roussy, Villejuif, France. Electronic address: florian.scotte@gustaveroussy.fr.
participants of the MASCC/ESMO Consensus Conference 2022. Electronic address: clinicalguidelines@esmo.org

Funding

World Health Organization 001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Radiation OncologyVomitingHumansNauseachemotherapyMASCC–ESMO Clinical Practice Guidelinenausea and vomitingpreventionradiotherapy

Identifiers

PMID38458657
PMCPMC10937211

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.